Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease - Authors' reply.

Competing Interests: AK has served as speaker for Norgine, Siemens, and Nordic Bioscience, and participated in advisory boards for Norgine and Siemens, all outside the submitted work. AK receives royalties from Gyldendal and has received equipment, drugs, or other services from Norgine, Siemens, and Echosense. MT has received speaking fees from Siemens Healthcare, Norgine, Echosens, and Tillotts Pharma; consulting fees from GE Healthcare; and participated in advisory boards for ID Liver and Alcohol & Society. All other authors declare no competing interests.